Problems related to treatment of beta-thalassaemia major.
New developments in the symptomatic treatment of beta-thalassaemia major are expected to improve the quality of life and survival of the patients. However, there are still many problems related to the clinical management of the patients due to the severity of the disease per se and the complications of blood transfusion and iron overload. Some of the problems related to the treatment of hypersplenism, post-transfusion complications, bone manifestations, hormonal deficiencies and haemosiderosis are reviewed in the light of recent investigations.
D000293:Adolescent; D000328:Adult; D001847:Bone Diseases / Q000209:etiology; D002648:Child; D002675:Child, Preschool; D003676:Deferoxamine / Q000008:administration & dosage / Q000627:therapeutic use; D004660:Encephalitis / Q000209:etiology; D005260:Female; D006728:Hormones / Q000172:deficiency; D006801:Humans; D007006:Hypogonadism / Q000209:etiology; D007239:Infections / Q000209:etiology; D007518:Isoantibodies / Q000276:immunology; D008297:Male; D012741:Sexual Maturation; D013156:Splenectomy / Q000009:adverse effects*; D013789:Thalassemia / Q000150:complications / Q000628:therapy*; D065227:Transfusion Reaction
D006728:Hormones; D007518:Isoantibodies; D003676:Deferoxamine